Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2016-01-19 Board/Management Inform…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Chief Financial Officer, Steve R. Martin, including his background, compensation, and severance terms. It also mentions a performance bonus awarded to the CEO. The key item reported is the change in senior management personnel. There are no financial statements or detailed financial results presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy statement, voting results, or a legal proceeding report. The primary focus is on management changes, which fits the Board/Management Information category (MANG). The document length (6873 characters) and detailed content support this classification with high confidence.
2016-01-19 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 11, 2016. It specifically mentions that the company has included a presentation handout to be used at the 34th Annual J.P. Morgan Healthcare Conference. The document states that the presentation is attached as Exhibit 99.1. The text does not contain detailed financial statements or comprehensive report content but rather announces the inclusion of a presentation for investor meetings. The document length is 2989 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, this type of document is best classified as an Investor Presentation (IP) since it is a detailed presentation for investors focusing on financials, strategy, and market position, and it is attached as an exhibit to the 8-K filing.
2016-01-11 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 4, 2016, reporting the entry into a material definitive agreement (an Asset Purchase Agreement) by AmpliPhi Biosciences Corporation. The content focuses on the acquisition of assets from Novolytics Limited, including payment terms and issuance of warrants. There are no financial statements or detailed financial performance data included. The document is a current report on a significant corporate event, specifically a material definitive agreement, which aligns with the category of Capital/Financing Update (CAP). It is not an annual or quarterly report, audit report, earnings release, or any other category. The length (5606 characters) and content confirm it is a full report of the event, not merely an announcement of a report publication or a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-01-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events. The content focuses on an amendment and restatement of the company's Code of Business Conduct and Ethics, which is a governance-related update. There is no financial data, earnings information, or detailed report content. The document is relatively short (3426 characters) and includes the amended Code of Conduct as an exhibit. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about governance changes but not a full governance report or management information filing. It is not a full governance report (CGR) because it is an amendment announcement, not a comprehensive governance document. Therefore, the classification is RNS with high confidence.
2015-11-18 English
FORM 10-Q
Interim / Quarterly Report Q3 2015
2015-11-16 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is the appointment of two new directors to the Board of Directors, including details about their stock options and compensation. This matches the description of announcements related to changes in the company's board or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. It specifically fits the category of Board/Management Information (MANG). The document length is 3379 characters, which is consistent with a typical 8-K filing for management changes. Therefore, the classification is MANG with high confidence.
2015-11-10 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.